GlassScriptPhysician profile
Donald R Doyle
NPI 1699766220
$1,243.75
in general payments reported to CMS, 2019-2025
25 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.22 · 2020: $36.57 · 2021: $59.82 · 2022: $135 · 2023: $447 · 2024: $328 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $221.20 | 2023-2025 | Wakix |
| Glaxosmithkline, LLC. | $194.89 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $119.59 | 2024 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $68.80 | 2025 | Lumryz |
| Resmed Corp | $68.43 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $63.29 | 2022-2023 | Uptravi, Opsumit |
| Itamar Medical INC | $62.37 | 2023 | Watchpatone |
| Allergan, INC. | $36.57 | 2020 | |
| Baxter Healthcare | $35.88 | 2024 | Perclot, Hillrom - Carnation Ambulatory Monitor |
| Bluewind Medical | $34.00 | 2025 | Revi |
| Genzyme Corporation | $33.32 | 2024 | |
| Merck Sharp & Dohme LLC | $32.72 | 2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $30.64 | 2025 | |
| Grifols USA, LLC | $25.16 | 2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $24.51 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.43 | 2023 | Ofev |
| Myriad Genetic Laboratories, INC. | $22.63 | 2024 | Prolaris |
| Dendreon Pharmaceuticals LLC | $21.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.31 | 2023 | Xarelto |
| Pulmonx Corporation | $19.76 | 2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Astrazeneca Pharmaceuticals LP | $17.86 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $17.75 | 2021 | |
| Boston Scientific Corporation | $16.81 | 2024 | Lithovue |
| 180 Medical, INC. | $16.60 | 2019 | |
| Medtronic, INC. | $15.61 | 2024 | Signia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.